Shire plc, of Dublin, said it completed its acquisition of Dyax Corp., of Cambridge, Mass., for $5.9 billion. Dyax shareholders may receive additional value through a nontradable contingent value right that will pay $4 in cash per Dyax share upon approval of next-generation hereditary angioedema drug DX-2930.